GlassScriptPhysician profile
Ma Catherine Valentin
NPI 1194448167
$1,632.17
in general payments reported to CMS, 2019-2025
17 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $459 · 2024: $618 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $261.39 | 2024-2025 | Wegovy, Ozempic |
| Abiomed | $186.86 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $159.91 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $133.71 | 2023 | Camzyos |
| Merck Sharp & Dohme LLC | $129.16 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $128.63 | 2023-2024 | |
| Pfizer INC. | $120.93 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $118.74 | 2025 | Amvuttra |
| Merz North America, INC. | $108.15 | 2024 | |
| Amgen INC. | $96.61 | 2024 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $43.16 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $39.01 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $26.90 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.70 | 2024 | |
| Scpharmaceuticals INC. | $24.74 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $14.74 | 2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $12.83 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ma Catherine Valentin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.